Online inquiry

IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13113MR)

This product GTTS-WQ13113MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ACVRL1 gene. The antibody can be applied in Hepatocellular carcinoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000020.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 94
UniProt ID P37023
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13113MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ677MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA 8H9
GTTS-WQ7427MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ3312MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ3702MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ4401MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ12643MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ9861MR IVTScrip™ mRNA-Anti-CD37, K7153A(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA K7153A
GTTS-WQ15594MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA VAL-1221
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW